Hereditary palmoplantar keratoderma

This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…

This early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 w…

This early-phase trial tests whether low doses of erlotinib, a drug originally used for cancer, can improve symptoms of rare genetic skin conditions called keratinopathies. About 44 adults with confirmed diagnoses will take increasing doses over 24 weeks. The goal is to see if it…

This study looks at how people with skin conditions (like eczema, psoriasis, or skin cancer) manage stress, feel lonely, and bounce back from challenges. Researchers will compare 375 adults with and without skin disease across 15 European countries using questionnaires. The goal …

This study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment resp…